Fintel on MSN1d
TD Cowen Downgrades J. M. Smucker (SJM)
Fintel reports that on January 8, 2025, TD Cowen downgraded their outlook for J. M. Smucker (NYSE:SJM) from Buy to Hold.
Hosted on MSN2d
TD Cowen Initiates Coverage of KalVista Pharmaceuticals (KALV) with Buy Recommendation
Fintel reports that on January 7, 2025, TD Cowen initiated coverage of KalVista Pharmaceuticals (NasdaqGM:KALV) with a Buy ...
TD Cowen's investment themes for 2025: Spotting opportunities and risks
Lisa Thomas, Managing Director and Deputy Head of Global Research at TD Cowen, discusses some of the key findings of a new TD Cowen report on the big investment themes of 2025, including shifting ...
Dick’s Sporting price target raised to $294 from $270 at TD Cowen
TD Cowen analyst John Kernan raised the firm’s price target on Dick’s Sporting to $294 from $270 and keeps a Buy rating on the shares. TD’s ...
New drugs mean higher prices — and a big year for Big Pharma
The cost of prescription drugs is set to climb in 2025 and beyond, according to TD Cowen’s 30th Annual Drug Pricing survey.
Trump's Ozempic tariffs, Zepbound on Medicare, and rising drug prices: Pharma news roundup
El Lilly’s blockbuster weight-loss drug Zepbound is now eligible for coverage under Medicare prescription drug plans, when ...
Consumer staples facing a tougher 2025 on MAHA initiatives, pivot to tech - analyst
“Two-thousand-twenty-four was a tough year for staples stocks, and 2025 is shaping up to be even tougher,” says TD Cowen ...
腾讯网2d
TD Cowen：预计特朗普政府将放宽银行使用加密货币的规则，但仍需保持谨慎
金色财经报道，投资银行 TD Cowen 表示，特朗普政府可能会为与银行合作的加密实体带来积极变化，但对这种新监管环境的预期应该是在“合理范围内的”。TD Cowen 华盛顿研究小组（由 Jaret Seiberg ...
TD Cowen Reaffirms Their Buy Rating on Embraer SA (ERJ)
TD Cowen analyst Jack Ayers maintained a Buy rating on Embraer SA (ERJ – Research Report) yesterday and set a price target of $50.00. The ...
腾讯网1d
TD Cowen：MAHA计划来袭，必需消费品股挑战升级
智通财经APP获悉，以罗伯特·莫斯科为首的 TD Cowen 分析师表示：“2024 年对于必需消费品股来说是艰难的一年，而 2025 ...
TD Cowen上调McKesson股票目标价，维持买入评级，看好其战略举措
分析师还考虑了McKesson最近的战略举措，包括收购FCS和剥离Rexall。这些变化已被纳入TD Cowen的模型，导致对公司2025财年和2026财年调整后每股收益（EPS）的预测更新，现估计分别为32.53美元和37.53美元。
TD Cowen上调Sana Biotech股票评级，因IST数据积极
周三，Sana Biotechnology股票获得TD Cowen分析师的评级上调，从持有上调至买入。此次上调是由于Sana宣布了积极的临时研究试验（IST）数据，显示HIP修饰的尸体胰岛细胞能够逃避免疫系统，并在一名1型糖尿病（T1D）患者体内产生C肽，而无需使用免疫抑制剂。 根据InvestingPro数据，Sana保持着强劲的流动性状况，现金多于债务，流动比率为4.47倍，为其临床开发提供了 ...